National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials (PDQ®)
Patient Version   Health Professional Version
Page Options
Print This Page
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Past Highlights
Related Links
Educational Materials About Clinical Trials

Clinical Trials: Questions and Answers

Questions to Ask Your Doctor

Drug Information from MedlinePlus
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases

Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase IV


Natural history/Epidemiology, Treatment


Active


18 and over


Pharmaceutical / Industry


CZOL446EAU22
NCT00434447

Trial Description

Summary

This study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the jaw(ONJ), overall safety and skeletal related events (SREs) beyond 12 months treatment

Eligibility Criteria

Inclusion criteria:

  • Documented bone metastases from breast cancer, prostate cancer or multiple myeloma
  • Prior treatment with zoledronic acid for 1-2 yrs
  • Life expectancy of at least 6 months

Exclusion criteria:

  • Prior treatment with bisphosphonates other than zoledronic acid
  • Abnormal kidney function
  • Current or previous dental problems or planned dental surgery
  • Pregnant or likely to become pregnant during the study

Other protocol-defined inclusion/exclusion criteria may apply

Trial Contact Information

Trial Lead Organizations/Sponsors

Novartis Pharmaceuticals Corporation

NovartisStudy Chair

Novartis BaselPh: 41 61 324 111

Trial Sites

Australia
Australian Capital Territory
  Canberra
 Study Site
New South Wales
  Concord
 Study Site
  Liverpool
 Study Site
  Wagga Wagga
 Study Site
Queensland
  Redcliffe
 Study Site
  Townsville
 Study Site
  Woolloongabba
 Study Site
Victoria
  Ballarat
 Study Site
  Box Hill
 Study Site
  Frankston
 Study Site

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00434447
Information obtained from ClinicalTrials.gov on May 27, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov